Furthermore, it was established that the targeted inhibition of mitochondrial Hsp90 with Gamitrinib reversed pulmonary vascular remodeling and improved cardiac output in two PAH models without perceptible toxicity. Here, HSP90AB1 is linked to pulmonary arterial hypertension.